Ultragenyx Pharmaceutical (RARE) Return on Equity (2014 - 2026)

Ultragenyx Pharmaceutical (RARE) has 13 years of Return on Equity data on file, last reported at 0.04% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.04%, up 4.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.04% (up 4.0% YoY), and the FY2025 annual result was 0.07%, down 7.0% from the prior year.
• Return on Equity retreated to 0.04% in Q1 2026 per RARE's latest filing, from 0.16% in the prior quarter.
• Over five years, Return on Equity peaked at 0.16% in Q4 2025 and troughed at 0.08% in Q3 2023.
• A 5-year average of 0.01% and a median of 0.01% in 2022 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2023 and 2025: Return on Equity fell 7 bps in 2023, then climbed 16 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.02% in 2022, then sank by 129 bps to 0.04% in 2023, then jumped by 99 bps to 0.0% in 2024, then jumped by 69874 bps to 0.16% in 2025, then tumbled by 76 bps to 0.04% in 2026.
• Business Quant data shows RARE's Return on Equity at 0.04% in Q1 2026, 0.16% in Q4 2025, and 0.0% in Q3 2025.